Trial Profile

A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zigakibart (Primary) ; Zigakibart (Primary)
Indications IgA nephropathy
Focus Adverse reactions; Proof of concept
Sponsors Chinook Therapeutics; Novartis Pharmaceuticals

Most Recent Events

26 Jun 2024 Planned End Date changed from 1 Oct 2026 to 13 Apr 2026.
09 Apr 2024 Planned End Date changed from 1 Apr 2026 to 1 Oct 2026.
01 Nov 2023 Planned End Date changed from 1 Jan 2026 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com